Academic Publications: (please feel free to email me for a PDF copy of any paper)
  1. Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C, Dhakal B, Lentzsch S, D'Souza A, Mohyuddin GR, Julian K, Midha S, Costello P, Kaiser M, Ng Liet Hing M, Harrison SJ, Cliff ERS, Mohan M. Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma. Blood Cancer Journal, 2024:14(137)
  2. Cliff ERS, Tessema FA. The Double-Edged Sword of Extremely High Prices for Gene Therapies in Sickle Cell Disease. JAMA, 2024 Aug 5.
  3. Cliff ERS, Russler-Germain DA, Daval CJR, Kesselheim AS. US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma. Journal of Clinical Oncology, 2024 Jul 25
  4. Cordas dos Santos DM, Tix T, Shouval R, Gafter-Gvili A, Alberge J-B, Cliff ERS, Theurich S, von Bergwelt-Baildon M, Ghobrial IM, Subklewe M, Perales M-A, Rejeski K. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nature Medicine 2024 Jul 8.
  5. Liu ITT, Kesselheim AS, Cliff ERS. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval. JAMA. 2024 Apr 7:e242396.
  6. Reynolds G, Maclean M, Cliff ERS, Teh BW, Thursky KA, Slavin MA, Anderson MA, Hawkes EA. Infections in lymphoma patients treated with bispecific antibodies: A systematic review and meta-analysis. Blood Advances. 2024 Jul 9;8(13):3555-3559.
  7. Ramachandran R, Shah D, Luo C, Shah V, Cliff ERS, Sanchorawala V, Lentzsch S, Chakraborty R. The Clinical Trials Landscape in Immunoglobulin Light Chain Amyloidosis: A Systematic Review. Blood Advances. 2024 Jul 9;8(13):3464-3467. 
  8. Leaver BA*, Cliff ERS*, Jefford M, Fogarty S, Zentner D. The paradox of platypnoea-orthodeoxia syndrome. Internal Medicine Journal. 2024 Apr;54(4):675-677
  9. Mellgard G, Gilligan M, Cliff ERS, Bhutani D, Mohyuddin GR, Eisenberger A, Lentzsch S, Chakraborty R. Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma. HemaSphere, 2024 Mar 20;8(3):e61.
  10. Hillis JM, Visser JJ, Cliff ERS, van der Geest-Aspers K, Bizzo BC, Dreyer KJ, Adams-Prassl J, Andriole KP. The lucent yet opaque challenge of regulating artificial intelligence in radiology. npj Digital Medicine, 2024 Mar 15;7(1):69.
  11. Ilerhunmwuwa NP, Abdul Khader AHS, Smith C, Cliff ERS, Booth CM, Rd EH, Aziz M, Lee-Smith W, Goodman A, Chakraborty R, Mohyuddin GR. Dietary interventions in cancer: a systematic review of all randomized controlled trials. Journal of the National Cancer Institute, 2024 Jul 1;116(7):1026-1034.
  12. Qian P, Willcox AW, Cliff ERS. Thrombotic complications of Immune Thrombocytopenic Purpura. The Lancet Haematology, 2024 Mar;11(3):e240.
  13. Wai SH, Lee ST, Cliff ERS, Bei M, Lee J, Hawkes EA, Chong G. Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma. Blood Advances. 2024 Feb 13;8(3):736-745.
  14. Kelkar AH, Cliff ERS, Jacobson CA, Abel GA, Dijk SW, Krijkamp EM, Redd R, Zurko JC, Hamadani M, Hunink MGM, Cutler C. Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A Cost-Effectiveness Analysis. Annals of Internal Medicine. 2023 Dec;176(12):1625-1637. 
  15. Abusamak A-A, Abusamak M, Al-Abbadi M, Rayyan A, Oran O, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R,
    ​Cliff ERS, Al Hadidi S.     Use of subjective minimizing language at hematology and oncology conferences: A systematic review. Journal of Cancer Policy. 2024 Mar;39:100461.
  16. Alrawabdeh J, Alzu'bi M, Alzyoud M, Odeh N, Hamadneh Y, Mian H, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Russler-Germain DA, Mehra N, Baggio D, Cliff ERS, Al Hadidi S. Characteristics of Post-hoc Subgroup Analyses of Oncology Clinical Trials: A Systematic Review. JNCI Cancer Spectrum. November 25, 2023
  17. Cliff ERS, Rome RS, Kesselheim AS, Rome BN. National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval. JAMA Network Open. 2023 Nov 1;6(11):e2343285.
  18. Najjar M, McCarron J, Cliff ERS, Berger K, Steensma DP, Al Hadidi S, Chakraborty R, Goodman A, Anto E, Greene T, Sborov D, Mohyuddin GR. Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA Network Open. 2023 Nov 1;6(11):e2342195.
  19. Mohyuddin GR, Chakraborty R, Cliff ERS, Derman BM. Cross-Sectional Survey of Clinician Preferences on Treatment of Smoldering Myeloma. eClinicalMedicine - The Lancet Discovery Science (October 19, 2023)
  20. Russler-Germain DA*, Cliff ERS*, Bartlett NL. Cell-of-Origin Effect of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma: No Ordinary Subgroup Analysis. Blood, October 6, 2023.
  21. Cliff ERS, Hilal T, Kesselheim AS. Complicated regulatory decisions when trial results are mixed: ibrutinib for mantle cell lymphoma. Nature Reviews Clinical Oncology, September 21, 2023.
  22. Kelkar AH, Shimony S, Cliff ERS, Stone RM. All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results. The Lancet Haematology 2023; 10(9): e706-e7.
  23. Lew TE*, Cliff ERS*, Dickinson M, Tam CS, Seymour JF, Blombery P, Bajel A, Ritchie D, Khot A. Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease. Leukemia and Lymphoma, 2023 
  24. Reynolds G*, Cliff ERS*, Mohyuddin GR, Popat R, Midha S, Ng Liet Hing M, Harrison SJ, Kesselheim AS, Teh BW. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Advances, 2023 
  25. Cliff ERS, Kelkar AH, Russler-Germain DA, Tessema FA, Raymakers AJN, Feldman WB, Kesselheim AS. The High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions. American Society of Clinical Oncology Education Book 43 (July 11, 2023)
  26. Cliff ERS, Kesselheim AS, Feldman WB. Ensuring ethical postprogression therapy for patients in randomized trial control arms. Journal of Clinical Oncology. 2023 
  27. Cliff ERS, Kesselheim AS, Rome BN, Feldman WB. Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020. JAMA Network Open. 2023;6(4):e237467.
  28. Cliff ERS, Reynolds G, Popat R, Teh B, Kesselheim AS, Mohyuddin GR. Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma. Journal of Clinical Oncology. 2023 Apr;41(10):1949-1951.
  29. Chakraborty R, Al Hadidi S, Cliff ERS, Mohyuddin GR. Is aggressive treatment of smoldering myeloma the path to curing myeloma? Blood Advances. 2023; 7(15):3932–3935.
  30. Cliff ERS, Janakiram M, Kesselheim AS. Melflufen: post-hoc subgroup analyses and the US FDA Oncologic Drugs Advisory Committee. The Lancet Haematology. 2023; 10(5):e314-e317.
  31. Cliff ERS*, Reynolds G*, Grigg A. Disseminated Invasive Mucormycosis Infection Following Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma. Clinical Hematology International. 2023; 5:71–77 
  32. Mohyuddin GR, Chakraborty R, Cliff ERS. The promise and harms of screening for plasma cell dyscrasias. British Journal of Haematology. 2023; 200(6):704–707
  33. Al Hadidi S, Cliff ERS. CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor–T-cell therapy in multiple myeloma. European Journal of Cancer. 2023; 182:1-2
  34. Cliff ERS, Pandya A. Pola-R-CHP for DLBCL: cost-effective at first glance. Blood. 2022; 140(25):2654–2655.
  35. Cliff ERS*, Merryman RW*, Armand P, Jacobson CA. Unresolved questions in the second-line use of CAR-T cells for diffuse large B cell lymphoma. Nature Medicine. 2022; 28:2458–2459.
  36. Cliff ERS, Mian H, Mohyuddin GR. Teclistamab in Relapsed or Refractory Multiple Myeloma. The New England Journal of Medicine. 2022;387(18):1721–3.
  37. Cliff ERS, Denholm JT. Geriatrician assessment and immortal time bias in the FiTR 2 study. The Lancet Healthy Longevity. 2022;3(11):e734.
  38. Cliff ERS, Kelkar AH. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease—Estimating the True Value. JAMA Neurology. 2022;79(11):1204.
  39. Cliff ERS, Dickinson M. Treatment of Mantle-Cell Lymphoma. The New England Journal of Medicine. 2022 Sep;387(12):1147-1148.
  40. Cliff ERS, Mohyuddin GR. Overall survival as a primary end point in multiple myeloma trials. Nature Reviews Clinical Oncology. 2022;19(9):565–6.
  41. Cliff ERS. A Decision Shared Is a Decision Halved. JAMA Oncology. 2022;8(6):825–826.
  42. Cliff ERS. The rollercoaster of vaccine-induced immune thrombotic thrombocytopenia. The Lancet Haematology. 2022;9(4):e246.
  43. Van Oekelen O, Birrer N, Wesson W, Galate VL, Cliff ERS, Goodman AM, Abdallah A-O, Chakraborty R, Prasad V, Mohyuddin GR. Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020. Blood Cancer Journal. 2022; 12:155.
  44. Major A, Cliff ERS, Ermann DA, Durani U, Russler-Germain DA. Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions. eJHaem. 2022, 3:3, 930-935
  45. Cliff ERS, Sasadeusz J, Visvanathan K, Grigg A. Very late-onset hepatitis B reactivation following chemoimmunotherapy. Leukemia & Lymphoma. 2022;63(4):991–5.
  46. Lew TE, Lin VS, Cliff ER, Blombery P, Thompson ER, Handunnetti SM, Westerman DA, Kuss BJ, Tam CS, Huang DCS, Seymour JF, Roberts AW, Anderson MA. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Advances. 2021;5(20):4054–8.
  47. Lew TE*, Cliff ERS*, Dickinson M, Tam CS, Seymour JF, Blombery P, Bajel A, Ritchie D, Khot A. T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease. Bone Marrow Transplantation 2021;56(11):2857–9.
  48. Cliff ERS, Szer J. We must grow the Australian Bone Marrow Donor Registry. Internal Medicine Journal 2021;51(11):1771–2.
  49. Lau L, Cliff ERS, Wong V, Wong H, Torkamani N, Eer A, Weickhardt A, Grossmann M. Hypocalcaemia following denosumab in prostate cancer: A clinical review. Clinical Endocrinology 2020;92(6):495–502.
  50. Misra S, Vedovato N, Cliff E, De Franco E, Hattersley AT, Ashcroft FM, Oliver NS. Permanent neonatal diabetes: combining sulfonylureas with insulin may be an effective treatment. Diabetic Medicine. 2018;35(9):1291–6.
  51. Fernandes B, Cliff ERS, Chowdhury A. Achieving self-sufficiency: training Australia’s future medical workforce. Australian Health Review. 2017; 42:640-642.
  52. Vedovato N, Cliff E, Proks P, Poovazhagi V, Flanagan SE, Ellard S, Hattersley AT, Ashcroft FM. Neonatal diabetes caused by a homozygous KCNJ11 mutation demonstrates that tiny changes in ATP sensitivity markedly affect diabetes risk. Diabetologia. 2016;59(7):1430–6.
  53. Dean JM, Cliff ERS, Freilich K, Gilfillan M. A campaign to improve the mental health of medical students. Medical Journal of Australia. 2016;204(9):346–346.​